This is the standing evidence sheet for Eli Lilly & (LLY): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $50.9 for each $1 of Eli Lilly &’s annual profit (a price-to-earnings ratio of 50.9). Across its own past decade the typical price tag was 65.6, which puts today at roughly the 27th percentile of the company’s own history.
The tape: what the stock itself has done
- Last price: $1,191.94 · 4% below its 52-week high
- Past 6 months: +7.7% · past 12 months: +55.6%
- Day-to-day temperament: jumpy (annualized volatility 38%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $28.3B | +15.4% | 21.7% | $6.12 |
| FY2022 | $28.5B | +0.8% | 23.8% | $6.9 |
| FY2023 | $34.1B | +19.6% | 19.2% | $5.8 |
| FY2024 | $45.0B | +32.0% | 28.2% | $11.71 |
| FY2025 | $65.2B | +44.7% | 39.5% | $22.95 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 34.1 | 45.0 | 65.2 | 88 to 96 | 100 to 115 |
| Net sales growth (%) | +35 | +32 | +45 | 35 to 47 | 13 to 25 |
| Operating margin (%) | 19.4 | 28.2 | 39.5 | 38 to 41 | 37 to 42 |
| Diluted EPS ($) | 5.80 | 11.71 | 22.95 | 28 to 36 | 30.51-44.51 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Eli Lilly &
Read the full report on Eli Lilly & in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-08-06. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
